<DOC>
	<DOCNO>NCT00192270</DOCNO>
	<brief_summary>The study design determine number dose CAIV-T require effectively immunize child adolescents 6 17 year age group .</brief_summary>
	<brief_title>Trial Assess Safety , Tolerability , Immunogenicity Influenza Virus Vaccine , Trivalent , Types A B , Live Cold-adapted ( CAIV-T ) Healthy Children</brief_title>
	<detailed_description>This phase II , prospective , open-label , multicenter , outpatient study design evaluate safety , tolerability , immunogenicity one two dose CAIV-T child adolescents 6 17 year age . Subjects allocate one three study group accord age time enrollment : study group one consist subject 6 9 year age , group two subject 10 12 year age , group three subject 13 17 year age . Approximately 450 subject ( ie , 150 subject per age group ) participate study schedule receive two intranasal dos CAIV-T separate 35 ± 7 day open-label manner .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>least 6 year 17 year age time enrollment ; , female postmenarche , provide negative pregnancy test ; · good health determine medical history , physical examination clinical judgement ; provide write informed consent ( appropriate accord national guideline ) whose parent ( ) legal guardian ( ) provide write informed consent nature study explain ; 13 , along parent ( ) legal guardian ( ) , available duration study ( approximately three month ) ; , together parent ( ) legal guardian ( ) , reach study staff postvaccination contact [ telephone , clinic visit home visit ] . perceive unavailable difficult contact evaluation study visit study period whose parent ( ) legal guardian ( ) perceive unreliable difficult contact evaluation study visit study period ; serious chronic disease ( e.g. , sign cardiac renal failure severe malnutrition ) , include progressive neurological disease ; Down 's syndrome know cytogenetic disorder ; know suspected disease immune system receive immunosuppressive therapy , include systemic corticosteroid ; receive blood product , include immunoglobulin , period six month prior vaccination conclusion study ; intent administer investigational vaccine agent one month prior enrollment conclusion study ; immunosuppressed immunocompromised individual living household ; , time prior entry study , receive dose influenza vaccine ( commercial investigational ) , two week prior entry study , receive dose influenza treatment ( commercial investigational ) document history hypersensitivity egg egg protein component study vaccine ; clinically confirm respiratory illness wheeze within two week prior enrollment ; receive aspirin ( acetylsalicylic acid ) aspirincontaining product two week prior enrollment use anticipate study ; administer live virus vaccine within one month prior enrollment expect receipt another live virus vaccine within one month vaccination study ; medical condition opinion investigator might interfere interpretation study result ; If criterion meet follow enrolment , subject exclude subsequent vaccine dosing . Note : A pregnant household member consider contraindication enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>